We have also demonstrated that salubrinal inhibits DNA repair in breast cancer cells [51] and that, like salubrinal, raphin‐1 decreases PED‐DHGG survival, induces DNA damage, and enhances DNA damage in the presence of the PARP‐1 inhibitor niraparib [10, 52]. This evidence concerns the gene PARP1 and breast carcinoma.